Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug curb weight gain in people with intellectual disabilities?

NCT ID NCT05744479

Disease control Sponsor: Centre for Addiction and Mental Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether metformin, a diabetes drug, can help adults with intellectual disabilities who have gained weight from antipsychotic medications. One hundred participants will receive either metformin or a placebo for 24 weeks, along with lifestyle advice. The goal is to see if metformin can safely reduce weight and improve health in this often-overlooked group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin
What this could lead to
If it works, this could provide a safe and accessible medication option to help manage weight gain caused by antipsychotics in people with intellectual disabilities.
What could go wrong
This is a small Phase 4 trial with only 100 participants, and metformin may not work for everyone. Side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stable outpatients * Age 16-65 years * Diagnosed with an IDD * On maintenance treatment with an antipsychotic (stable dose for ≥3 months). * BMI must be ≥30 kg/m2, OR ≥27 kg/m2 with at least one weight-related comorbidity (treated or untreated) such as: hypertension, dyslipidaemia, obstructive sleep apnea, or impaired fasting glucose, OR \>=25 for individuals who have gained \> 5% body weight in association with AP use. * Females of child-bearing age must be on one of the following regular contraceptives: 1. Agree to abstain from sex for the duration of the trial or 2. A barrier method of a diaphragm with spermicide and/or Latex condom or 3. An oral contraceptive agent, implantable contraceptive or an injectable contraceptive for at least six months prior to entering the study and will continue its use throughout the study, or 4. An intrauterine device, or 5. Partner has had a vasectomy at least 3 months prior to study start Exclusion Criteria: * Females who are nursing, currently pregnant, or have a positive pregnancy test * Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, hepatic, renal, or pulmonary disease * Previous treatment and lack of efficacy or tolerability with metformin * History or diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (TD2) or fasting blood work, HbA1c \> 6.5% * History of metabolic acidosis or lactic acidosis * Treatment with weight-lowering agents * Medications with significant renal impact * Major medical or surgical event in the preceding 3 months * Acute suicidal risk. * Moderate to severe substance use disorder, other than caffein or nicotine use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Developmental disability are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

developmental disability intellectual disability Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Developmental disability Intellectual disability Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    RECRUITING

    Toronto, Ontario, M6J1H3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.